Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients
- PMID: 21505847
- PMCID: PMC4276133
- DOI: 10.1007/s10549-011-1510-6
Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients
Abstract
Male breast cancer (MBC) is a rare disease in the U.S., accounting for less than 1% of all breast cancers. Rates of MBC in Africa are more variable than in the U.S., therefore, understanding the risk factors involved in a population like Egypt can clarify the nature of MBC. The polyglutamine tract (QT) is a variable region of the androgen receptor (AR), a nuclear receptor which is important in modulating androgen actions and generally inhibits growth in breast tissue. It is hypothesized that a long QT results in weaker AR activity over the lifetime, resulting in less AR mediated control over cellular division and higher risk of MBC. As a corollary, we expect to see a distribution skewed toward longer QTs in MBC patients compared to controls and overall relatively longer QT's in populations with higher rates of MBC. This study aimed to investigate for the first time the distribution of AR QT lengths among MBC patients in Egypt. Paraffin-embedded tumor tissues from 44 Egyptian MBC patients were analyzed for this polymorphism. Amplification followed by fragment length analysis revealed QT length. For the control series, blood from 43 Egyptian males without a family or personal history of breast or prostate cancers was collected and analyzed similarly. There was no significant difference between patients and controls with respect to mean QT length (P = 0.84; means were 19.5 ± 2.8 and 19.3 ± 4.2, for patients and controls, respectively). Though, short QT lengths were more prevalent among controls (14.0%), but almost absent in cases (2.3%). Although the mean lengths were not different in cases and controls, the near absence of short tracts in cases suggests a possible protective effect of very short QT lengths against MBC. In populations in which there is variable incidence of MBC by region, investigations of the distribution of AR QT lengths are warranted to further delineate its role as a risk factor in MBC.
Figures
Similar articles
-
Long CAG repeat sequence and protein expression of androgen receptor considered as prognostic indicators in male breast carcinoma.PLoS One. 2012;7(12):e52271. doi: 10.1371/journal.pone.0052271. Epub 2012 Dec 14. PLoS One. 2012. PMID: 23272232 Free PMC article.
-
Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients.Breast Dis. 2011;33(1):17-26. doi: 10.3233/BD-2010-0323. Breast Dis. 2011. PMID: 22142662 Free PMC article.
-
Androgen receptor gene alterations in Finnish male breast cancer.Breast Cancer Res Treat. 2003 Jan;77(2):167-70. doi: 10.1023/a:1021369508561. Breast Cancer Res Treat. 2003. PMID: 12602915
-
Clinical aspect of male breast cancer: a burgeoning and unaddressed issue.Mol Biol Rep. 2025 May 13;52(1):452. doi: 10.1007/s11033-025-10558-4. Mol Biol Rep. 2025. PMID: 40358767 Review.
-
The biology of male breast cancer.Breast. 2018 Apr;38:132-135. doi: 10.1016/j.breast.2018.01.001. Epub 2018 Jan 6. Breast. 2018. PMID: 29316513 Review.
Cited by
-
Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women.PLoS One. 2012;7(7):e40494. doi: 10.1371/journal.pone.0040494. Epub 2012 Jul 11. PLoS One. 2012. PMID: 22792352 Free PMC article.
-
Long CAG repeat sequence and protein expression of androgen receptor considered as prognostic indicators in male breast carcinoma.PLoS One. 2012;7(12):e52271. doi: 10.1371/journal.pone.0052271. Epub 2012 Dec 14. PLoS One. 2012. PMID: 23272232 Free PMC article.
-
Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients.Breast Dis. 2011;33(1):17-26. doi: 10.3233/BD-2010-0323. Breast Dis. 2011. PMID: 22142662 Free PMC article.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300. 2010. doi:10.3322/caac.20073. - PubMed
-
- Freedman L, Edwards BK, Ries LAG, Al-Kayed S, Barchana M, Ibrahim AS, Komodiki C, Young JL. Overview and summary data. In: Freedman LS, Edwards BK, Ries LAG, Young JL, editors. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. Bethesda, MD: 2006. pp. 1–27. NIH Pub. No. 06-5873.
-
- Incidence Des Cancer a Rabat, 2005. Cancer du Sein; Rabat, Morocco: 2009. pp. 45–47.
-
- Oguntola AS, Aderonmu AO, Adeoti ML, Olatoke SA, Akanbi O, Agodirin SO. Male breast cancer in LAUTECH teaching hospital Osogbo, South Western Nigeria. Niger Postgrad Med J. 2009;16:166–170. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials